Midregional proatrial naturetic peptide (MRproANP) and copeptin (COPAVP) as predictors of all cause mortality in recently diagnosed mild to moderate COPD – Results from COSYCONET
Rattachement africain : de, us. Niveau de preuve : code pays fourni par la source.
Le résumé fourni par la source
Background : MRproANP and COPAVP are prognostic markers for mortality in chronic obstructive pulmonary disease (COPD). Furthermore, these biomarkers predict mortality due to cardiovascular diseases, which are important prognostically determining comorbidities in patients with COPD. However, less is known about these biomarkers in recently diagnosed mild to moderate COPD. Therefore, we analyzed these biomarkers as potential predictors of mortality in recently diagnosed mild to moderate COPD. Methods: The blood biomarkers considered were copeptin (COPAVP), midregional adrenomedullin (MRproADM), midregional proatrial naturetic peptide (MRproANP), and fibrinogen. Analyses were performed in patients with stable “recently diagnosed mild to moderate COPD” defined by GOLD grades 0-2 and diagnosis of COPD≤5 years prior to inclusion into the COSYCONET cohort ( CO PD and Sy stemic Consequences – Co morbidities Net work), using Cox regression analysis with stepwise adjustment for multiple COPD characteristics, comorbidities, troponin and NT-proBNP. Results: 655 patients with recently diagnosed mild to moderate COPD were included. In the initial regression model, 43 of 655 patients died during the 6-year follow-up, in the final model 27 of 487. Regression analyses with adjustment for confounders identified COPAVP and MRproANP as statistically robust biomarkers (p<0.05 each) of all-cause mortality, while MRproADM and fibrinogen were not. The fourth quartile of MRproANP (97 pmol/L) was associated with a hazard ratio of 4.5 (95%CI: 1.6; 12.8), and the fourth quartile of COPAVP (9.2 pmol/L) with 3.0 (1.1; 8.0). The results for MRproANP were confirmed in the total cohort of grade 0-4 (n=1470 finally). Conclusion: In patients with recently diagnosed mild to moderate COPD, elevated values of COPVP and in particular MRproANP were robust, independent biomarkers for all-cause mortality risk after adjustment for multiple other factors. This suggests that these markers might be considered in the risk assessment of early COPD Publication History Article published online: 18 March 2025 © 2025. Thieme. All rights reserved. Georg Thieme Verlag KG Oswald-Hesse-Straße 50, 70469 Stuttgart, Germany
Ce résumé expose les affirmations des auteurs. BNTIC ne l’interprète pas comme une validation indépendante des résultats.
Le contrôle bibliographique ouvert
DOI retrouvé dans Crossref DOI retrouvé ; titre concordant.
- Titre Crossref
- Midregional proatrial naturetic peptide (MRproANP) and copeptin (COPAVP) as predictors of all cause mortality in recently diagnosed mild to moderate COPD – Results from COSYCONET
- Date Crossref
- 01/03/2025
- Éditeur
- Georg Thieme Verlag KG
- Type
- proceedings-article
Ce recoupement confirme des métadonnées liées au DOI. Il ne confirme ni la méthode ni les conclusions de l’étude, et il ne compte pas comme une seconde source scientifique indépendante.
Où se fait cette recherche
-
University Medical Center Freiburg pays non établi dans la noticeÉtablissement de santé
-
Universitätsklinikum Gießen und Marburg pays non établi dans la noticeÉtablissement de santé
-
Universitätsklinikum des Saarlandes pays non établi dans la noticeÉtablissement de santé
-
Klinikum Itzehoe pays non établi dans la noticeÉtablissement de santé
-
Heidelberg University pays non établi dans la noticeUniversité ou école supérieure
-
University Hospital Heidelberg pays non établi dans la noticeÉtablissement de santé
-
Hautklinik Heidelberg pays non établi dans la noticeÉtablissement de santé
-
Philipps University of Marburg pays non établi dans la noticeUniversité ou école supérieure
-
German Center for Lung Research pays non établi dans la noticeStructure de recherche
-
Velocity Clinical Research (United States) pays non établi dans la noticeEntreprise
-
Medizinische Hochschule Hannover pays non établi dans la noticeUniversité ou école supérieure
-
Zimmer Biomet (United States) pays non établi dans la noticeEntreprise
University Medical Center Freiburg, Universitätsklinikum Gießen und Marburg et Universitätsklinikum des Saarlandes, avec 9 autres affiliations.
Une affiliation ne permet pas de déduire la nationalité d’un auteur.